PYC Therapeutics (ASX:PYC) - Stock Price, News & Analysis

Resumen acción PYC

PYC Therapeutics Limited, empresa dedicada al desarrollo de fármacos, se dedica en Australia al descubrimiento y desarrollo de soluciones farmacológicas en las áreas de la terapéutica del ARN.

Acerca de la empresa

PYC fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 30.13%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de PYC Therapeutics Limited

Aroa Biosurgery

ASX:ARX

AU$197.9m

Imugene

ASX:IMU

AU$768.6m

Race Oncology

ASX:RAC

AU$268.7m

Dimerix

ASX:DXB

AU$156.6m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for PYC Therapeutics
Historical stock prices
Current Share Price	AU$0.094
52 Week High	AU$0.12
52 Week Low	AU$0.05
Beta	0.63
1 Month Change	17.50%
3 Month Change	3.30%
1 Year Change	46.88%
3 Year Change	-46.29%
5 Year Change	308.70%
Change since IPO	-63.85%

Noticias y actualizaciones recientes

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

Apr 10

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

Nov 10

Recent updates

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Feb 20

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

Jan 26

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

Dec 22

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

Nov 17

Rentabilidad de los accionistas

	PYC	AU Biotechs	Mercado AU
7D	10.6%	-1.9%	-0.8%
1Y	46.9%	-6.3%	7.8%

Rentabilidad frente al sector: PYC superó al sector Australian Biotechs , que obtuvo un rendimiento del -1.4% el año pasado.

Rentabilidad vs. Mercado: PYC superó al mercado Australian, que obtuvo un rendimiento del 11.4% el año pasado.

Volatilidad de los precios

Is PYC's price volatile compared to industry and market?
PYC volatility
PYC Average Weekly Movement	10.6%
Biotechs Industry Average Movement	11.2%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	16.9%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: PYC no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PYC (12%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2001	n/a	Rohan Hockings	https://pyctx.com

PYC Therapeutics Limited, una empresa de desarrollo de fármacos, se dedica al descubrimiento y desarrollo de soluciones farmacológicas en las áreas de la terapéutica del ARN en Australia. Los programas de desarrollo preclínico de la empresa incluyen VP-001, un programa farmacológico para la retinosis pigmentaria tipo 11; PYC-001, un programa farmacológico para el tratamiento de la atrofia óptica autosómica dominante; y PYC-002 un programa farmacológico para el tratamiento de un trastorno grave del neurodesarrollo. También se centra en el desarrollo de programas para enfermedades renales, del neurodesarrollo, de la retina y del sistema nervioso central.

Resumen de fundamentos de PYC Therapeutics Limited

¿Cómo se comparan los beneficios e ingresos de PYC Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de PYC
Capitalización bursátil	AU$397.89m
Beneficios(TTM)	-AU$21.65m
Ingresos (TTM)	AU$21.24m

18.7x

Ratio precio-beneficio

-18.4x

Ratio precio-beneficio

¿Está PYC sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PYC
Ingresos	AU$21.24m
Coste de los ingresos	AU$0
Beneficio bruto	AU$21.24m
Otros gastos	AU$42.89m
Beneficios	-AU$21.65m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.0051
Margen bruto	100.00%
Margen de beneficio neto	-101.90%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado PYC a largo plazo?

Ver rendimiento histórico y comparativa

Resumen acción PYC

Recompensas

Análisis de riesgos

Competidores de PYC Therapeutics Limited

ASX:ARX

AU$197.9m

ASX:IMU

AU$768.6m

ASX:RAC

AU$268.7m

ASX:DXB

AU$156.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

Recent updates

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 74.657343 million.

New major risk - Financial position

Pyc Therapeutics Announces the Results of A Study Conducted in Human 3-Dimensional Models Derived from Patients with End-Stage Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease

Is PYC Therapeutics (ASX:PYC) In A Good Position To Deliver On Growth Plans?

PYC Therapeutics Limited, Annual General Meeting, Nov 24, 2023

New minor risk - Financial data availability

PYC Therapeutics Limited Announces US FDA Designates PYC's Lead as a Fast Track Development Program

New minor risk - Share price stability

We Think PYC Therapeutics (ASX:PYC) Needs To Drive Business Growth Carefully

Non-Executive Chair of the Board recently bought AU$85k worth of stock

PYC Therapeutics Limited, Annual General Meeting, Jul 05, 2023

Pyc Appoints Andrew Taylor as Joint Company Secretary

PYC Therapeutics Limited Announces the Submission of Investigational New Drug Application with the US Food and Drug Administration

Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn Situation

High number of new and inexperienced directors

PYC Therapeutics Limited Announces Successful Toxicology Studies Pave Way for Human Trials

PYC Therapeutics Limited, Annual General Meeting, Nov 23, 2022

PYC Therapeutics Limited Announces Central Nervous System Drug Program Added to PYC Pipeline

Non-Executive Chair of the Board recently bought AU$103k worth of stock

PYC Therapeutics Limited Announces Exemplary PK Study Results Move RP11 Program Closer to First in Human Trials

High number of new and inexperienced directors

Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In Growth

PYC Therapeutics Limited Enters into the Next Phase of Preclinical Development for VP-001

PYC Therapeutics Announces Comprehensive Preclinical Results Demonstrating VP-002 Program's Potential as the First Disease Modifying Therapy for Autosomal Dominant Optic Atrophy

CEO & Director exercised options to buy AU$1.6m worth of stock.

PYC Therapeutics to Develop A New Generation of RNA Therapeutics

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease ­ Autosomal Dominant Optic Atrophy

We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn Rate

PYC Therapeutics Limited Appoints Michael Rosenblatt, MD, to Its Board of Directors

PYC's Lead Investigational Drug, VP-001, Demonstrates Another Key Functional Improvement in Patient-Derived Models - a First for Any Rp11 Treatment to-Date

PYC Therapeutics Names Glenn Noronha as Chief Development Officer

Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)

Non-Executive Chair of the Board recently bought AU$81k worth of stock

Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?

What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor Composition

PYC Therapeutics Limited Announces Visual Evidence of Lead Drugs Efficacy

PYC Therapeutics Limited Appoints Sahm Nasseri as CEO of Us Operations and as Director of the Board

We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business Growth

PYC Therapeutics Announces to Developing New Treatments for Severe Unmet Patient Needs

Doug Huey Not to Seek Re Election At PYC Therapeutics Limited

PYC Therapeutics Limited Develops New Treatments for Severe Unmet Patient Needs

PYC Therapeutics Limited Files for Intellectual Property Protection for the New Drug Candidate

PYC Therapeutics Limited Announces CEO Changes

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de PYC Therapeutics Limited

18.7x

-18.4x

Beneficios e Ingresos

PYC Therapeutics Limited Announces Second Investigational Drug Candidate Restores the Levels of the Target Protein Towards Normal in Models Derived from Patients with the Indicated Disease Autosomal Dominant Optic Atrophy